IM Cannabis (NASDAQ:IMCC) Trading 2.3% Higher – What’s Next?

IM Cannabis Corp. (NASDAQ:IMCC)’s share price traded up 2.3% on Friday . The company traded as high as $0.30 and last traded at $0.2899. 467,449 shares traded hands during mid-day trading, a decline of 37% from the average session volume of 740,018 shares. The stock had previously closed at $0.2834.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of IM Cannabis in a research report on Friday, April 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

IM Cannabis Stock Performance

The business’s 50-day simple moving average is $0.54 and its two-hundred day simple moving average is $1.14. The firm has a market cap of $1.80 million, a price-to-earnings ratio of -0.21 and a beta of 2.00. The company has a quick ratio of 0.54, a current ratio of 0.67 and a debt-to-equity ratio of 0.25.

IM Cannabis (NASDAQ:IMCC) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.95). The firm had revenue of $11.25 million during the quarter, compared to analyst estimates of $15.66 million. IM Cannabis had a negative return on equity of 585.96% and a negative net margin of 21.24%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of IMCC. Hidden Cove Wealth Management LLC acquired a new position in shares of IM Cannabis during the 3rd quarter worth about $27,000. Yorkville Advisors Global LP acquired a new position in shares of IM Cannabis during the 3rd quarter worth about $1,452,000. Finally, DRW Securities LLC acquired a new position in shares of IM Cannabis during the 4th quarter worth about $32,000. Institutional investors and hedge funds own 7.68% of the company’s stock.

IM Cannabis Company Profile

IM Cannabis Corp is a vertically integrated medical cannabis company based in Israel, specializing in the research, cultivation and production of cannabis-based formulations. The company holds three key licenses granted by the Israeli Ministry of Health, covering cultivation, possession and distribution of medical-grade cannabis. Its production facilities in Moshav Yizrael feature controlled-environment agriculture chambers designed to deliver consistent, high-purity cannabinoid profiles.

The company’s product portfolio includes standardized cannabis oils, distillates, vaporizer cartridges and topical preparations, all formulated under Good Manufacturing Practice (GMP) standards.